Enjoy complimentary customisation on priority with our Enterprise License!
The bipolar disorder therapeutics market size is forecast to increase by USD 787.02 million at a CAGR of 2.68% between 2023 and 2028. The market is experiencing significant growth due to the rising incidence of this mental health condition. According to the National Institute of Mental Health, approximately 2.8% of adults in the United States have bipolar disorder. The market is driven by the development of innovative treatments, including tricyclic antidepressant drugs, beta blockers, anti-psychotic drugs, lithium (Li) element, vasopressin hormone, and anticonvulsant drugs. These medications help manage the symptoms of bipolar disorder, which include extreme mood swings between mania and depression. Another trend in the market is the increasing prevalence of personalized treatment approaches due to advances in genetics and neuroscience. This personalization allows for more effective treatment plans tailored to individual patients, leading to better outcomes. However, the stigma surrounding mental health issues remains a challenge, hindering diagnosis and treatment. The market is expected to continue growing as research and development efforts continue to uncover new treatment options and improve existing ones.
Bipolar disorder, also known as manic-depressive illness, is a mental health condition characterized by extreme mood swings between mania and depression. According to the National Institute of Mental Health, approximately 2.8% of adults in the US are affected by this disorder. The need for effective therapeutic options to manage the symptoms of bipolar disorder is a significant concern for medical institutions, scientific organizations, and government entities. Government efforts have been instrumental in funding research and development of new therapeutics for bipolar disorder. For instance, the National Institute of Mental Health (NIMH) has been investing in studies to explore the underlying causes of bipolar disorder and identify potential treatments.
Moreover, medical institutions and scientific organizations are focusing on developing various classes of drugs to manage the symptoms of bipolar disorder. These include mood stabilizers, anticonvulsants, antipsychotic drugs, antidepressant drugs, and anti-anxiety drugs. Mood stabilizers, such as lithium (Li) element and valproate, are commonly used to treat bipolar disorder. Lithium, a naturally occurring element, has been in use since the 1940s and is considered the gold standard for treating bipolar I disorder. Lithium works by stabilizing the mood by regulating the activity of certain chemicals in the brain. Anticonvulsant drugs, such as carbamazepine, valproate, and lamotrigine, are also used to manage the symptoms of bipolar disorder.
Additionally, these drugs are primarily used to treat epilepsy but have been found to be effective in stabilizing mood in individuals with bipolar disorder. Antipsychotic drugs, such as cariprazine, aripiprazole, olanzapine, and lurasidone, are used to manage the manic and psychotic symptoms of bipolar disorder. These drugs work by blocking the dopamine and serotonin receptors in the brain, helping to reduce the symptoms of mania and psychosis. Antidepressant drugs, such as tricyclic antidepressant drugs and selective serotonin reuptake inhibitors (SSRIs), are used to treat the depressive symptoms of bipolar disorder. However, these drugs can increase the risk of manic episodes and are typically used in combination with mood stabilizers.
Also, beta blockers, such as propranolol, are sometimes used off-label to manage the symptoms of mania and agitation in individuals with bipolar disorder. These drugs work by blocking the action of adrenaline, a hormone that can contribute to manic symptoms. The route of administration of these drugs can vary, with oral administration being the most common. However, parenteral administration, such as intramuscular or intravenous, may be necessary in certain situations, such as during manic episodes or hospitalization. Scientific organizations are also exploring alternative approaches to treating bipolar disorder, such as the use of vasopressin hormone and diabetes insipidus.
The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million" for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.
The antipsychotics segment is estimated to witness significant growth during the forecast period. In the international market, the antipsychotic drug class segment is a leading contender, accounting for a substantial revenue share. Individuals diagnosed with bipolar disorder experience mood swings, delusions, and hallucinations, which are effectively addressed through this drug class. Antipsychotics have gained prominence due to their ability to regulate mood and diminish the severity of manic or depressive episodes. Notable antipsychotic medications for bipolar disorders include Seroquel, Olanzapine, and Aripiprazole. These drugs have been indispensable in managing bipolar disorders for an extended period and are frequently incorporated into comprehensive treatment plans, often in conjunction with mood stabilizers.
Get a glance at the market share of various segments Request Free Sample
The antipsychotics segment was valued at USD 2.29 billion in 2018 and showed a gradual increase during the forecast period.
North America is estimated to contribute 41% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
For more insights on the market share of various regions Request Free Sample
In North America, the market holds a substantial share due to several factors. The region's advanced healthcare system, high prevalence of bipolar disorder cases, and growing emphasis on mental health conditions are significant contributors to this market dominance. Leading pharmaceutical companies like Pfizer and Bristol-Myers Squibb, who are actively engaged in research and development to cater to the unmet needs of bipolar disorder patients, characterize this market. The demand for antipsychotic drugs, antidepressants, and mood stabilizers is on the rise in North America, leading to market growth. Additionally, improved access to bipolar disorder therapeutics has been facilitated through expanded insurance coverage for mental health services and the integration of mobile apps and telemedicine for remote consultations.
Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
The increasing incidence of bipolar disorder is the key driver of the market. The global market for bipolar disorder therapeutics in the United States is experiencing significant growth due to several factors. The increasing awareness and reduction of stigma surrounding mental health conditions, such as bipolar disorder, have led to more individuals seeking diagnosis and treatment. This trend is driven by advancements in diagnostic techniques and a growing recognition of the importance of mental health. According to recent studies, over 3 million Americans are living with bipolar disorder in 2023, and this number is projected to increase during the forecast period. Government efforts, medical institutions, and scientific organizations are playing a crucial role in advancing the development of effective treatments for bipolar disorder.
Moreover, these entities are investing in research and funding clinical trials to explore new therapeutic options. Currently, mood stabilizers, anticonvulsants, and antipsychotic drugs are the primary treatments for managing bipolar disorder symptoms. However, ongoing research is focused on developing more targeted and personalized treatments, including anti-depressant drugs and alternative therapies. The increasing prevalence of bipolar disorder, coupled with the ongoing research and development efforts, is expected to fuel the growth of the market in the United States. This trend is a positive sign for individuals living with bipolar disorder, as it means that more effective and personalized treatment options are on the horizon.
Additionally, the availability of these treatments through medical institutions and pharmacies will make them more accessible to those in need. Overall, the future of bipolar disorder therapeutics in the United States is promising, with continued advancements and innovations on the horizon.
The increased prevalence of personalized treatment due to advances in genetics and neuroscience is the upcoming trend in the market. In the realm of bipolar disorder therapeutics, a significant shift is occurring toward personalized treatment approaches. This trend is driven by advancements in neuroscience and genetics, which are enabling medical professionals to tailor care for individual patients. Genetic testing plays a crucial role in this process, as it can identify unique genetic markers linked to bipolar disorder. This information allows doctors to prescribe medications with a greater likelihood of efficacy for each patient.
Moreover, neuroimaging techniques, such as functional magnetic resonance imaging (fMRI) and magnetic resonance spectroscopy (MRS), offer deeper insights into the anatomical and functional abnormalities of the brain in bipolar disorder. These imaging tools aid in treatment selection and monitoring, contributing to more effective care. Tricyclic antidepressant drugs, beta blockers, anti-psychotic drugs, lithium (Li), vasopressin hormone, diabetes insipidus, and anticonvulsant drugs are among the therapeutic options used in the treatment of bipolar disorder.
The stigma surrounding mental health issues is a key challenge affecting the market growth. The global market for bipolar disorder therapeutics faces a substantial obstacle due to the lingering societal stigma surrounding mental health issues. Despite growing knowledge and recognition, many individuals hesitate to pursue treatment out of fear of societal rejection or shame. This reluctance can lead to non-adherence to prescribed medications, delayed diagnoses, and limited access to care. For example, an individual with bipolar disorder may be reluctant to disclose their condition or seek professional help due to the potential judgment of others, making it more challenging for them to obtain appropriate therapeutics. To address this issue, continuous efforts are required to decrease the social stigma towards mental health concerns, enhance public understanding, and encourage open dialogues that encourage early and effective treatment for bipolar disorder.
However, anti-anxiety drugs, such as Cariprazine, Aripiprazole, Olanzapine, and Lurasidone, play a crucial role in managing bipolar disorder symptoms. These medications are available in various routes of administration, including oral and parenteral forms. It is essential to reduce the stigma surrounding mental health to ensure that individuals receive the necessary treatment for bipolar disorder promptly. Keywords: bipolar disorder therapeutics, anti-anxiety drugs, Cariprazine, Aripiprazole, Olanzapine, Lurasidone, societal stigma, mental health, public awareness, open dialogues. The persistent societal stigma surrounding mental health issues poses a significant challenge to The market. Despite increasing awareness and understanding, many individuals are reluctant to seek treatment due to fear of societal rejection or shame.
The market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
AbbVie Inc: The company offers products such as VRAYLAR as an adjunctive treatment for major depressive disorder.
The market research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Bipolar disorder, also known as manic depression, is a mental health condition characterized by periods of depression and elevated mood. The therapeutic market for bipolar disorder is witnessing significant growth due to various factors. Government efforts to increase public awareness and improve access to mental health services have led to an increase in the diagnosis and treatment of bipolar disorder. Medical institutions and scientific organizations are conducting extensive research to develop effective therapeutics for bipolar disorder. Mood stabilizers, antipsychotic drugs, antidepressant drugs, and anti-anxiety drugs are commonly used for the treatment of bipolar disorder. Lithium (Li) element, vasopressin hormone, and diabetes insipid are also used in the treatment of bipolar disorder.
Moreover, mood stabilizers such as anticonvulsant drugs like cariprazine and aripiprazole, olanzapine, and lurasidone are effective in managing the symptoms of bipolar disorder. The route of administration for these medications can be oral or parenteral. Antipsychotic drugs like tricyclic antidepressant drugs, beta blockers, and monoamine oxidase inhibitors are also used in the treatment of bipolar disorder. Combination therapies using a combination of medications and psychotherapy are becoming increasingly popular in the treatment of bipolar disorder. Digital health technologies like telemedicine, mobile apps, and other digital solutions are also being explored to improve access to mental health services and enhance the effectiveness of treatments.
In conclusion, the use of antidepressant drugs like tricyclic antidepressants and selective serotonin reuptake inhibitors (SSRIs) is a subject of ongoing research in the treatment of bipolar disorder. Benzodiazepines are used to manage anxiety symptoms associated with bipolar disorder. The disease burden of bipolar disorder is high, leading to increased healthcare expenditure on mental health conditions. The side effects of medications used in the treatment of bipolar disorder are a major concern, and ongoing research is focused on developing new drugs with improved safety profiles. The mechanism of action of various drugs used in the treatment of bipolar disorder is being studied to develop more effective and targeted therapies.
|
Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
161 |
|
Base year |
2023 |
|
Historic period |
2018-2022 |
|
Forecast period |
2024-2028 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 2.68% |
|
Market growth 2024-2028 |
USD 787.02 million |
|
Market structure |
Fragmented |
|
YoY growth 2023-2024(%) |
1.96 |
|
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
|
Performing market contribution |
North America at 41% |
|
Key countries |
US, Canada, Germany, UK, and China |
|
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
|
Key companies profiled |
AbbVie Inc., Amneal Pharmaceuticals Inc., Astellas Pharma Inc., AstraZeneca Plc, Bristol Myers Squibb Co., Eli Lilly and Co., Gedeon Richter Plc, GlaxoSmithKline Plc, H Lundbeck AS, Intra-Cellular Therapies Inc., Mallinckrodt Plc, Novartis AG, Otsuka Holdings Co. Ltd., Pfizer Inc., Sumitomo Pharma Co. Ltd., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., The London Psychiatry Centre, Wockhardt Ltd., and Zydus Lifesciences Ltd. |
|
Market dynamics |
Parent market analysis, market growth inducers and obstacles, market forecast, fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, market condition analysis for the forecast period |
|
Customization purview |
If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Drug Class
7 Market Segmentation by Distribution Channel
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get the report (PDF) sent to your email within minutes.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
